HOMEPartneringSuccess Stories

Co-located Exhibition:

Sponsors' Microsites

Press Releases

From the Organizer
- Change of Booth No.
Research Center for Medical Plant Resources National Institutes of Biomedical Innovation Health and Nutrition: D-13


National Center Biobank Network ― Introduction to 6NC―

Lonza Cell & Gene Therapy Manufacturing Facility in Houston, TX, Area to Complete Construction on Schedule in 2017

Lonza to Increase and Expand Capabilities for Drug Product Services for Parenteral Dosage Forms

Lonza Pharma&Biotech Launches Ibex™ Solutions – An Innovative New Concept in Biological Manufacturing and Development


SIRION Biotech and Vibalogics partner to offer complete Adeno-Associated Virus (AAV) services
SIRION Biotech (Bavarian Pavilion: D06)
SIRION and Vibalogics


Press release Dutch Food CRC NIZO presents microbiome capability with the Holland Pavilion at BioJapan 2017.


INCJ and 9 portfolio companies in the health and medical field to jointly exhibit at BioJapan 2017

Development of Rehabilitation system based on real-time electroencephalogram analysis

Production of genetic test strip enabling simple infectious diseases test and export to ASEAN countries


【AIST Sponsor Seminar】Challenge to merging digital and biotechnologies


Inauguration of Shonan Research Center

CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research

Takeda Announces the Start of Operations for AXCELEAD at its Shonan Research Center

Takeda and Noile-Immune Biotech Collaborate to Advance Next Generation CAR-T Cell Therapy Effective for Solid Tumors


【Exhibitor Presentation】IT changes drug developments / Device technologies of AIST


DefiniGEN announces collaboration with Kishida Chemical to develop their iPSC-derived disease model business in the Japanese pharmaceutical market

Success Stories

Berlin Partner / Cluster HealthCapital Berlin

Berlin Partner

Berlin Partner

"At BioJapan we felt an incredible interest from Japanese companies towards R&D- and development-partnerships with our cluster HealthCapital. It was easy for us to meet the right people and we hope to facilitate even more collaborations this year."

Carolin Clement,
Head of Unit Biotech | Pharma

Participants in BioJapan since 2012

Main Partnering Objectives:

“Building bridges between Japan and Berlin when it comes to research collaboration or market access – for the SMEs in our cluster and Japanese companies with an interest in the EU market.”


“Our networks have been steadily growing. We were able to build good relations with influential Japanese clusters and initiatives. Those contacts have already helped our companies to engage in partnerships in Japan.”

Sphere Fluidics Ltd. (via the EU-Japan Centre for Industrial Cooperation)

First participated in BioJapan 2016

Sphere Fluidics

Sphere Fluidics

"The partnering process was very well organized and the exhibition was of a very high standard. Excellent overall."

Dr Frank F. Craig, CEO,
Sphere Fluidics

Main Partnering Objectives:

“To learn more about the Japanese pharmaceutical market and to find a distributor.”

  • Identified 5 potential distributors and already set to sign up two of them.
  • Learned more about the Japanese market and identified sales leads
  • Will launch new single cell analysis system (Cyto-Mine®) in Japan in May 2017.

Proteo-Science Center, Ehime University (Protein Island Matsuyama Project)

  • Continuous participation in BioJapan from 2013-2016. Booth presentation organized by collaboration of Ehime Univ., Ehime Prefecture & CellFree Sciences Co., Ltd.
  • Forged two research partnerships with a domestic chemical company and a global pharmaceutical company.
  • Developed new protein expression kit based on collaboration between CellFree Sciences and a domestic chemical company.
  • Announced technical lecture course in presenter seminar, and obtained new participants.
Takafumi TSUBOI

“The matching system and partnering events, provided by BioJapan, gave us chance to appeal our technologies and seeds to pharmaceuticals and industries. Scientists in Ehime University attended discussions with business partners, and explained their technologies by themselves. It contributed to benefit both academia and company sides”.

Director, Proteo-Science Center
Takafumi TSUBOI

Cell-Free Membrane Protein Production System

Commercialization and the product sold:
Cell-Free Membrane Protein Production System

Membrane proteins are an important drug target. We developed a new method to synthesize membrane proteins in vitro. Large amount of membrane proteins can be synthesized in a short time with high success rate, and it is useful to prepare immunizing antigen for antibody development against membrane proteins. A cell-free membrane protein synthesis kit based on our technology is available from CellFree Sciences. Many global and domestic companies introduced the kit.

Waseda University Research Collaboration and Promotion Center 

  • Continuous participation in BioJapan from 2010-2014.
  • Concluded 3 research partnerships with domestic and foreign partners, worth 200,000 USD in funding and licensing fees.
  • Discussing joint research with a potential partner met at BioJapan2014 .
Kuniki KINO

“BioJapan is a perfect opportunity to present our university’s research results and to get a grasp of the market. Trough the partnering meetings, we better understand the market value of our technology in relation to market needs. This is very effective to give feed back to our researchers and to evaluate the intellectual property in our university”.

Director, Research Collaboration and Promotion Center

Kuniki KINO

Melanoma diagnosis support system

industry-academia collaboration
- Melanoma diagnosis support system -

Because Japan has a relatively low number of cases of Melanoma, we were seeking clinical research for our diagnosis support system overseas. Through BioJapan we managed to start a foreign clinical study and at BioJapan 2014 we received another interesting offer. Together with a foreign company, we also extend the application range of our system, and it led to a successful technology transfer. (50,000 USD)


| Sitemap |

© 2017 JTB Communication Design, Inc. All rights reserved.